In Brief: Selfcare/J&J LifeScan
This article was originally published in The Gray Sheet
Executive Summary
Selfcare/J&J LifeScan: Finalize distribution agreement under which Waltham, Massachusetts-based Selfcare's advanced electrochemical blood glucose monitoring system will be distributed by the J&J subsidiary. The advanced system has not received FDA clearance, although a simpler model was 510(k) cleared June 28 ("The Gray Sheet" June 17, p. 26). LifeScan has paid Selfcare a $7 mil. success fee, and a LifeScan affiliate has converted its loans of $13.7 mil. to Selfcare into 201,622 shares of Selfcare common stock. Pursuant to a Nov. 10, 1995 agreement between LifeScan and Selfcare, the LifeScan affiliate will receive approximately 278,000 additional shares equal to 5% of all common stock...
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.